AtriCure to Present at the Needham & Company’s 18th Annual Healthcare Conference
April 01 2019 - 10:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced that it will present at the Needham
& Company’s 18th Annual Healthcare Conference in New York on
Wednesday, April 10, 2019. Management is scheduled to present
at 3:30 p.m. Eastern Time. A live audio webcast of the
presentation may be accessed by visiting the Investors page of
AtriCure’s corporate website at ir.atricure.com. A replay of the
presentation will be available for 90 days following the
presentation.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage
Exclusion System products are the most widely sold LAA management
devices worldwide, with more than 170,000 implanted to date. For
more information, visit AtriCure.com or follow us on Twitter
@AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190401005507/en/
Andy WadeAtriCure, Inc.Senior Vice President and Chief Financial
Officer(513) 755-4564awade@atricure.com
Lynn Pieper LewisGilmartin GroupInvestor Relations(415)
937-5402lynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Sep 2023 to Sep 2024